Exhibit 10.19

CONFIDENTIAL TREATMENT REQUESTED

Portions of this Exhibit have been redacted pursuant to a request for
confidential treatment under Rule 24b-2 of the General Rules and Regulations
under the Securities Exchange Act of 1934, as amended. Omitted information,
marked “[*]” in this Exhibit, has been filed separately with the Securities and
Exchange Commission together with such request for confidential treatment.

 

AMENDMENT #9

TO LIENSE AGREEMENT ID 2014-0052

Between Purdue Research Foundation and Endocyte, Inc.

 

THIS AMENDMENT, made and entered into this 25th day of August 2017 (“Amendment
Effective Date”) amends the Master License Agreement entered into and effective
as of July 1, 2013 and all subsequent Amendments (hereinafter “Agreement”)
between Purdue Research Foundation (hereinafter known as “PRF”) and Endocyte,
Inc. (hereinafter known as “Endocyte”) with respect to the matters addressed in
this Agreement.

WHEREAS, Purdue University continues to develop technologies and scientific
advances in the laboratory of Professor Philip Low funded by Endocyte, Inc.; and

WHEREAS, Endocyte wishes to continue licensing such technologies and scientific
advances under the Agreement,

NOW THEREFORE, the parties hereto do hereby agree as follows:

 

1.

The following Elected Eligible Disclosure is added to Schedule A for a Target
under Section 1.20(ii):

 

Title of Elected Eligible Disclosure

[*]

PRF Reference Number of Elected Eligible Disclosure

67750

Contributors of the Elected Eligible Disclosure

Philip S. Low and Jyoti Roy

 

2.

The following Licensed Patents are added to Schedule A of the Agreement for a
Target under Section 1.20(ii).

 

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

 

--------------------------------------------------------------------------------

 

 

 

 

 

 

 

 

PRF Ref #

Title of Application

Application Number

Inventors

Filing Date

Country

Status

67750-01

[*]

[*]

Philip S. Low and Jyoti Roy

12/14/2016

US (Provisional)

Filed

67750-02

[*]

[*]

Philip S. Low and Jyoti Roy

3/6/2017

US (Provisional)

Filed

 

All other terms and conditions of the original agreement remain unchanged and in
effect.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the
date first above written.

 

Purdue Research FoundationEndocyte, Inc.

By: _/s/ Brooke Beier____________By: _/s/ Mike Sherman__________

Name:Brooke Beier             Name:  Mike Sherman

 

Title: Executive Director, OTC           Title:  President & CEO

 

Date:     11-08-2017                        Date:     11-01-17   

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

 

--------------------------------------------------------------------------------

 

 

AMENDMENT #10

TO LICENSE AGREEMENT ID 2014-0052

Between Purdue Research Foundation and Endocyte, Inc.

 

THIS AMENDMENT, made and entered into this 25th day of August 2017 (“Amendment
Effective Date”) amends the Master License Agreement entered into and effective
as of July 1, 2013 and all subsequent Amendments (hereinafter “Agreement”)
between Purdue Research Foundation (hereinafter known as “PRF”) and Endocyte,
Inc. (hereinafter known as “Endocyte”) with respect to the matters addressed in
this Agreement.

WHEREAS, Purdue University continues to develop technologies and scientific
advances in the laboratory of Professor Philip Low funded by Endocyte, Inc.; and

WHEREAS, Endocyte wishes to continue licensing such technologies and scientific
advances under the Agreement,

NOW THEREFORE, the parties hereto do hereby agree as follows:

1.

The following Elected Eligible Disclosure is added to Schedule A of the
Agreement for a Target under Section 1.20(ii).

 

Title of Elected Eligible Disclosure

[*]

PRF Reference Number of Elected Eligible Disclosure

67751

Contributors of the Elected Eligible Disclosure

Philip S. Low and Jyoti Roy

 

2.

The following Licensed Patents are added to Schedule A of the Agreement for a
Target under Section 1.20(ii).

PRF Ref #

Title

App #

Inventors

Filing Date

Country

Status

67751-01

[*]

[*]

Philip S. Low

Jyoti Roy

December 14, 2016

US (provisional)

Filed

 

All other terms and conditions of the original agreement remain unchanged and in
effect.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the
date first above written.

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

 

--------------------------------------------------------------------------------

 

 

Purdue Research FoundationEndocyte, Inc.

By: _/s/ Brooke Beier__________By: _/s/ Mike Sherman___________

Name:Brooke Beier             Name:  Mike Sherman

 

Title: Executive Director, OTC           Title:  President & CEO

 

Date:      November 8, 2017    Date:    11-01-17  

 

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

 

--------------------------------------------------------------------------------